Trelagliptin Succinate, with the Chemical Abstracts Service (CAS) number 1029877-94-8, is a highly effective DPP-4 inhibitor used for the management of type 2 diabetes. Known for its extended-release formulation, trelagliptin provides sustained glucose control, helping to reduce HbA1c levels and improve overall blood sugar regulation. It is widely recognized for its once-weekly dose schedule, offering a more convenient treatment regimen for patients compared to daily alternatives.

Trelagliptin Succinate plays a significant role in controlling blood sugar by inhibiting DPP-4 (dipeptidyl peptidase-4), an enzyme that deactivates incretin hormones. Incretins help regulate insulin release, making trelagliptin an essential option for patients with type 2 diabetes who need long-term management. Its once-weekly dosing is a key advantage for patients who require effective yet convenient treatment.

Trelagliptin Succinate, CAS 1029877-94-8, DPP-4 inhibitor, type 2 diabetes treatment, extended-release diabetes medication, Trelagliptin specifications, pharmaceutical API, diabetes research, Trelagliptin suppliers.

This product is suitable for use in the pharmaceutical industry for the development of oral anti-diabetic formulations and for research applications in the management of type 2 diabetes.